OTC:DROR
Dror Ortho-Design, Inc.
A loss-making orthopedic medical device manufacturer with no reported revenue and deepening financial deficits.
Key Metrics
Investment Thesis
Bull Case
At its current valuation, the stock trades at negligible value relative to its substantial paid-in capital of $19.1M, offering a potential turnaround opportunity if management can successfully pivot to revenue generation. The heavy R&D investment indicates a dedicated team working on proprietary orthopedic technologies that could yield significant returns upon market entry.
Bear Case
The company is burning through cash at an unsustainable rate with no income-producing assets, making it highly likely to face insolvency or require dilutive equity financing soon. Investors should avoid this stock as the financial statements reveal a company in deep distress with negative equity and zero sales over multiple reporting periods.
About Dror Ortho-Design, Inc.
Dror Ortho-Design, Inc. (DROR) is a medical device manufacturer focused on orthopedic solutions, serving hospitals and surgical centers with specialized implantable products. The company operates primarily in the healthcare technology sector, though recent financials indicate a complete lack of revenue generation. Investors should approach this entity with caution as it has accumulated significant operating losses and negative shareholder equity over the last five years.
Analysis
Management Discussion
Management has failed to generate any revenue in the latest reporting period while recording a net loss of $2.5M despite zero cost of revenue, suggesting potential accounting adjustments or complete lack of commercial activity. The cash flow from operations turned negative at $2.1M, depleting cash reserves by over $300k in the year and forcing reliance on financing inflows to stay afloat.
Industry Overview
The orthopedic medical device industry is characterized by high regulatory barriers, significant R&D requirements, and long development cycles for new implantable technologies. While market demand for joint replacement and trauma care products remains robust, new entrants without an established revenue history face extreme challenges in gaining market share against incumbents.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $178.7K | $4.4M | $5.2M | $2.2M |
| Operating Income | $-178.7K | $-4.4M | $-5.2M | $-2.2M |
| R&D | — | $1.0M | $1.5M | $815.9K |
| G&A | $93.0K | $1.1M | $1.4M | $1.4M |
| Stock-Based Comp | — | $2.3M | $2.2M | $39.2K |
| Depreciation | — | $670 | $4.0K | $4.9K |
| Other OpEx | $85.8K | $2.3M | $2.2M | $39.2K |
| Non-Operating Income | $-14 | $810.8K | $-552.0K | $-321.9K |
| Interest Expense | $14 | — | — | — |
| Pre-Tax Income | $-178.8K | $-3.6M | $-5.8M | $-2.5M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-178.8K | $-3.6M | $-5.8M | $-2.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-178.8K | $-3.6M | $-5.8M | $-2.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-178.8K | $-3.6M | $-5.8M | $-2.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $60.4K | $3.5M | $638.6K | $238.8K |
| Cash & Equivalents | $55.1K | $3.3M | — | — |
| Prepaid Expenses | — | — | $89.1K | $10.2K |
| Other Current Assets | $5.3K | $114.1K | $549.4K | $228.5K |
| Long-Term Assets | $0 | $2.3K | $24.1K | $20.2K |
| PP&E (Net) | — | $2.3K | $24.1K | $20.2K |
| Other LT Assets | — | $0 | $0 | $0 |
| Total Assets | $60.4K | $3.5M | $662.7K | $258.9K |
| Current Liabilities | $784.3K | $297.1K | $906.7K | $3.0M |
| Accounts Payable | — | $106.8K | $215.4K | $113.6K |
| Other Current Liab | $783.7K | $190.3K | $691.4K | $2.8M |
| Long-Term Liabilities | $0 | $5.2K | $124.0K | $176.1K |
| Total Liabilities | $784.3K | $302.3K | $1.0M | $3.1M |
| Shareholders' Equity | $-723.9K | $3.2M | $-368.0K | $-2.9M |
| Paid-In Capital | — | $16.8M | $19.0M | $19.1M |
| Retained Earnings | $-41.8M | $-13.7M | $-19.5M | $-22.1M |
| Total L&E | $60.4K | $3.5M | $662.7K | $258.9K |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-178.8K | $-3.6M | $-5.8M | $-2.5M |
| Non-Cash Adjustments | $2.2K | $1.5M | $2.4M | $573.2K |
| Working Capital Changes | $45.7K | $-313.8K | $588.7K | $-86.3K |
| Cash from Operations | $-130.9K | $-2.4M | $-2.7M | $-2.1M |
| Capital Expenditures | — | — | $25.8K | $966 |
| Cash from Investing | — | $18.0K | $-25.8K | $-966 |
| Cash from Financing | — | $4.7M | $0 | $1.8M |
| FX Effect | $0 | $0 | $-30.7K | $-11.9K |
| Net Change in Cash | $-130.9K | $2.3M | $-2.8M | $-320.9K |
| Beginning Cash | $185.9K | $1.0M | $3.3M | $549.4K |
| Ending Cash | $55.1K | $3.3M | $549.4K | $228.5K |
Frequently Asked Questions
How does Dror Ortho-Design, Inc. make money?
The company's financial structure suggests a single non-performing segment where cost of goods sold is zero, implying potential inventory write-downs or discontinued operations rather than active sales. The substantial research and development expenditures ($815k) contrast sharply with $0 gross profit, indicating capitalization of costs or an inability to monetize R&D efforts in the current period.
What are the main risks for DROR?
The company faces a critical liquidity crisis with cash reserves dropping from $549k to $228k while operating expenses consume $2.2M annually. Severe financial distress is evident through negative net assets of $2.9M and a retained earnings deficit exceeding $22M, threatening continued operations. The total liabilities of $3.1M significantly outweigh current assets, creating a precarious solvency position with no revenue stream to service debt.
What is DROR's competitive advantage?
The company has invested heavily in intellectual property and specialized manufacturing capabilities through high R&D spend, though these assets currently generate no income. The existing patent portfolio may offer future licensing opportunities if product development can be completed and commercialized successfully.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.